Carcinoma, Non-Small-Cell Lung clinical trials

The registry lists 7,621 studies for Carcinoma, Non-Small-Cell Lung across more than 10 countries. 1,836 are recruiting or about to start. 6,208 of them are mainly about Carcinoma, Non-Small-Cell Lung (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 8,603 studies for Carcinoma, Non-Small-Cell Lung. How that becomes 7,617 here

This page counts the studies the registry files under Carcinoma, Non-Small-Cell Lung, and those it files under no condition that list Carcinoma, Non-Small-Cell Lungthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

8,603Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−146List Carcinoma, Non-Small-Cell Lung as a condition, but the registry did not file them under itMost often written as “Non-small Cell Lung Cancer Metastatic” (12), “EGFR Positive Non-small Cell Lung Cancer” (9), and “Advanced Non-small Cell Lung Cancer” (8). The registry filed them under other conditions only, most often Lung Neoplasms (38) and Neoplasm Metastasis (18).
−843Match it another way745 name it in the title, 18 in a keyword, and 80 by a synonym or other text the search reads.
7,614Counted here and found by its search519 of them list Carcinoma, Non-Small-Cell Lung in their own words; the registry filed them under no condition.
+3
Counted here, but its search does not find them
7,617The count on this page

Get an email when these change. Save the Carcinoma, Non-Small-Cell Lung studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 2,949
Recruiting: 1,327
Terminated: 985
Status unknown: 876
Active, not recruiting: 653
Not yet recruiting: 463

Phase

Phase 2: 3,396
Phase 1: 2,073
Phase 3: 917
Phase 4: 105
Early Phase 1: 63

Where

United States: 3,366
China: 1,877
France: 872
Spain: 851
Italy: 713
Korea, Republic of: 700

Who runs them

AstraZeneca (199) · National Cancer Institute (NCI) (176) · Eli Lilly and Company (147) · Hoffmann-La Roche (139) · Pfizer (128) · M.D. Anderson Cancer Center (109) · Sun Yat-sen University (102) · Novartis Pharmaceuticals (95)

What is being tested here

Drugs under test in Carcinoma, Non-Small-Cell Lung studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Aflutinib	27	5	36
Pembrolizumab	26	29	119
Nivolumab	22	19	109
Pemetrexed	21	46	212
Anlotinib	21	7	60
Carboplatin	20	48	266
Osimertinib	20	10	83
Tislelizumab	19	10	38
Ivonescimab	19	3	21
Cemiplimab	18	6	27

Drug classes tested here Immune checkpoint inhibitors 255 open · Tyrosine kinase inhibitors (TKIs) 203 open · Antibody-drug conjugates (ADCs) 38 open · Antimetabolites 27 open · Antimitotic agents 25 open

Coming up

325phase 3 studies under way

658studies finish main data collection within a year59 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Phase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 2026Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer · Phase 3 · Tianjin Medical University Cancer Institute and Hospital
Nov 2026Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 3 · Medicine Invention Design, Inc
Nov 2026Avelumab Program Rollover Study · Phase 3 · EMD Serono Research & Development Institute, Inc.
Nov 2026Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） · Phase 3 · Second Affiliated Hospital, Zhejiang University, School of Medicine
Dec 2026A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer · Phase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Dec 2026A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) · Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
Dec 2026A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC · Phase 3 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Dec 2026Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC · Phase 3 · Stanford University
Dec 2026To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy · Phase 3 · Allist Pharmaceuticals, Inc.

Who these studies take

Of the 1,327 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger. 34 (3%) take children under 18. 1 (<1%) are for women only and 2 (<1%) for men only; 40 (3%) take healthy volunteers.

Recruiting studies that take each age, of 1,327
Age	Women	Men
10	28 (2%)	28 (2%)
18	1,270 (96%)	1,270 (96%)
30	1,303 (98%)	1,303 (98%)
40	1,306 (98%)	1,306 (98%)
50	1,308 (99%)	1,308 (99%)
65	1,319 (99%)	1,320 (99%)
75	1,286 (97%)	1,287 (97%)
85	1,055 (80%)	1,055 (80%)

Across all 7,621 studies, recruiting or not: 14% stop at 75 or younger and 1% at 65; 4% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Non-Small-Cell Lung studies take

Of 1,047 phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	50 mo31–70 · 699 studies	49 mo29–66 · 473 studies	54 mo36–80 · 226 studies
Phase 1/2	63 mo42–80 · 432 studies	58 mo39–77 · 309 studies	69 mo46–107 · 123 studies
Phase 2	48 mo30–76 · 1,047 studies	37 mo24–59 · 317 studies	56 mo36–84 · 730 studies
Phase 2/3	53 mo40–… · 56 studies	—	—
Phase 3	45 mo30–69 · 424 studies	39 mo27–57 · 315 studies	81 mo49–129 · 109 studies
Phase 4	34 mo22–48 · 43 studies	—	—
Interventional, no phase	51 mo26–97 · 359 studies	—	52 mo28–98 · 343 studies
Observational	55 mo35–83 · 498 studies	49 mo31–64 · 142 studies	58 mo36–126 · 356 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out